

# DISCOVERY & DEVELOPMENT US 2025

October 2 - 3, 2025 | San Diego, CA

## Conference Brochure

Equipping biopharma innovators with critical intelligence and partners needed to discover, develop and deliver first-in-class drugs rapidly



**8**  
Content Tracks  
Across Two Days



**200+**  
Pre-Arranged  
Meetings



**35+**  
Partners



**1,000+**  
Attendees

### Composed of 3 Focus Areas



Drug  
Discovery



Automation &  
Robotics



Formulation &  
Delivery

## Meet Your KEYNOTE SPEAKERS



DAY ONE | 09:15 ✦

### STEVE TURNER

Chief Executive Officer,  
**Pangio Biosystems** &  
Former Founding Chief  
Executive Officer, **PacBio**



DAY TWO | 09:00 ✦

### RAY DESHAIES

Former Senior Vice  
President of  
Global Research,  
**Amgen**



**Book Now!** Complimentary Industry,  
Academic or Investor Guest Passes Available

Register ✦

Sponsor



Co-located with Biologics US 2025  
[> More Information](#)



[oxfordglobal.com/discovery-development/events/discovery-development-us-2025](https://oxfordglobal.com/discovery-development/events/discovery-development-us-2025)





# WELCOME TO Discovery & Development US 2025

Welcome to Discovery & Development US 2025 – where we unify 3 stand-out focus areas under one roof – Drug Discovery, Formulation & Delivery and Automation & Robotics.

Join us for two days of high-level discussion & tailored content, spotlighting novel modalities & emerging computational tools to foster innovation. Our Drug Discovery program highlights the latest breakthroughs in target identification & validation, medicinal & AI-guided computational chemistry & hit identification & screening. Join our exclusive track shining a light on degraders & molecular glues – where you'll hear case studies on the current technology & platforms for their discovery & design.

Our featured automation & robotics sessions features all things AI & data-powered, from streamlining lab workflows with automation and FAIR data management & digital transformation to implementing robotics within labs to improve productivity & efficiency.

Finally, join our Formulation & Delivery program to learn about the latest advancements in the formulation of large and small molecule-based drugs, developments in RNA, peptide and oligonucleotide design; and explore the innovations in the delivery of complex and challenging therapeutics.

This year, Discovery & Development US goes even further – co-located with Biologics US 2025, we offer 1000+ attendees the unique opportunity to engage across both communities and forging the path to the next generation of therapies that will transform lives and reshape the future of healthcare.

## Charlotte Catley

Portfolio Director – Discovery & Development Brand, Oxford Global



## Unlock The Latest News & Insights

Sign up for our monthly newsletter to keep up with all things Discovery

[Click Here](#)



## BROCHURE CONTENTS

[Welcome](#)

[Benefits of Attending](#)

[Sponsors](#)

[Special Event Features](#)

[Agenda at a Glance](#)

[Featured Speakers: Discovery](#)

[Featured Speakers: Formulation](#)

[All Speakers](#)

[Full Programme: Day One](#)

[Full Programme: Day Two](#)

[Venue Information](#)

[Book Now](#)

[LinkedIn](#)  
[@OGConferences](#)





WHAT'S NEW

## Benefits Of Attending



**Stay ahead of the curve:** uncover how novel modalities like PROTACs, molecular glues, bispecific antibodies and beyond are reshaping the innovation landscape.



**The latest in computational R&D:** explore how AI-guided chemistry, advanced modeling and predictive tools are accelerating decision-making from discovery to human dose prediction.



**Benchmark your lab against industry leaders:** discover how automation & robotics can improve productivity for your workflows & exponentially decrease development time.



**The use of AI – is it hype or is it justified?** Make your decision by hearing from the experts using AI, data & digital transformation to drive drug discovery!



**Discover the formulation breakthroughs redefining what's possible:** from lipid and polymeric nanoparticles to automation technology and high-dosage therapies.



**Keep your finger on the pulse of next-gen drug delivery:** hear how innovators are advancing RNA therapeutics, long-acting injectables, nanoparticle carriers, implants and inhalation approaches.

## DON'T MISS THESE Interactive Features

16:15 | Day 1

**Panel Discussion:**

The Status of AI/ML in Drug  
Discovery: Where Are We and Where  
Are We Going?

08:30 | Day 2

**Roundtable Discussion:**

IP Considerations in Early Discovery  
& Development

12:10 | Day 2

**Panel Discussion:**

Sustainability Impact of Different  
Drug Delivery Methods

16:15 | Day 1

**Industry Workshop:**

The Changing Landscape of RNA  
Design & Delivery

08:30 | Day 2

**Roundtable Discussion:**

From Drug Product Development to  
Overcoming Regulatory Hurdles

BROCHURE  
CONTENTS

Welcome

Benefits of  
Attending

Sponsors

Special  
Event  
Features

Agenda at  
a Glance

Featured  
Speakers:  
Discovery

Featured  
Speakers:  
Formulation

All Speakers

Full  
Programme:  
Day One

Full  
Programme:  
Day Two

Venue  
Information

Book Now

LinkedIn  
@OGConferences



## WHY PARTNER WITH OXFORD GLOBAL?

**At Oxford Global, our mission is to curate personalised experiences that foster community and inspire innovation.**

We believe in the power of networking, connection, and knowledge to deliver quality products and services that exceed expectations. Partnering with Oxford Global means having a dedicated team committed to helping you achieve your goals and navigating the industry's ever-changing landscape.

### ✓ Arrange 1-1 Meetings

Benefit from guaranteed one-to-one face time with your key prospects, with detailed pre-meeting information provided to enable effective and productive conversations.

### ✓ Speaking Opportunities

Showcase your company's recent work to a relevant and highly engaged audience.

### ✓ Host Panel & Roundtable Discussions

Feature alongside key opinion leaders to discuss current hot topics and highlight your company's expertise.

### ✓ Organise Workshops

Demonstrate best practice within the industry in front of your peers with case studies from your clients.

### ✓ Exhibit your Products & Solutions

Promote your offerings and ensure delegates know where to find you with a prominent brand presence in the exhibition hall.

### ✓ Digital Marketing & Lead Generation

Accessing the Oxford Global database, amplify your thought leadership and branding messaging through our digital content initiatives.

**LEARN MORE** 



DRIVE INNOVATION & ACCELERATE RESEARCH

## Who Is Partnering?

### Platinum Sponsors



### Gold Sponsors



### Silver Sponsors



Crystal Pharmatech

HUB ORGANOIDS



FRONTEO



### BROCHURE CONTENTS

Welcome

Benefits of  
Attending

Sponsors

Special  
Event  
Features

Agenda at  
a Glance

Featured  
Speakers:  
Discovery

Featured  
Speakers:  
Formulation

All Speakers

Full  
Programme:  
Day One

Full  
Programme:  
Day Two

Venue  
Information

Book Now

LinkedIn  
@OGConferences





## WHY PARTNER WITH OXFORD GLOBAL?

**At Oxford Global, our mission is to curate personalised experiences that foster community and inspire innovation.**

We believe in the power of networking, connection, and knowledge to deliver quality products and services that exceed expectations. Partnering with Oxford Global means having a dedicated team committed to helping you achieve your goals and navigating the industry's ever-changing landscape.

### ✓ Arrange 1-1 Meetings

Benefit from guaranteed one-to-one face time with your key prospects, with detailed pre-meeting information provided to enable effective and productive conversations.

### ✓ Speaking Opportunities

Showcase your company's recent work to a relevant and highly engaged audience.

### ✓ Host Panel & Roundtable Discussions

Feature alongside key opinion leaders to discuss current hot topics and highlight your company's expertise.

### ✓ Organise Workshops

Demonstrate best practice within the industry in front of your peers with case studies from your clients.

### ✓ Exhibit your Products & Solutions

Promote your offerings and ensure delegates know where to find you with a prominent brand presence in the exhibition hall.

### ✓ Digital Marketing & Lead Generation

Accessing the Oxford Global database, amplify your thought leadership and branding messaging through our digital content initiatives.

**LEARN MORE** 




DRIVE INNOVATION & ACCELERATE RESEARCH

## Who Is Partnering?

### Bronze Sponsors



### Network & Program Sponsors



### Start Up Zone



## BROCHURE CONTENTS

Welcome

Benefits of  
Attending

Sponsors

Special  
Event  
Features

Agenda at  
a Glance

Featured  
Speakers:  
Discovery

Featured  
Speakers:  
Formulation

All Speakers

Full  
Programme:  
Day One

Full  
Programme:  
Day Two

Venue  
Information

Book Now

LinkedIn  
@OGConferences



# Big Attendance Meets Intimate Connections

 GALA DINNER OPENING SPEECH



**RICK EWING, Vice President, Head of Chemistry**



Received the 2023 American Chemical Society (ACS) Philadelphia Section Award

## 'Innovation & Breakthroughs Under the Stars' Garden Party

Join us for our 'Innovations & Breakthroughs Under the Stars' Garden Party at the end of Day 1 at the Eventide Gardens, Sheraton San Diego by the Marina. This is your chance to mix and mingle with the brightest minds in the industry in a vibrant, open-air setting, complete with gourmet food stations, refreshing drinks, and a relaxed garden-party vibe.

Whether you're coming to connect, unwind, or simply enjoy a summer evening, this is the can't - miss celebration of the season, all under the California night sky.

## Day 1 Opening Keynote Address: The Single-Molecule Revolution Makes Landfall In Drug Discovery: Where We Are Now & What's To Come

- STEVE TURNER, Chief Executive Officer, Pangio Biosystems & Former Founding Chief Executive Officer, PacBio
- Don't miss Steve opening the event with his talk at 9:15 on Day 1.



## Day 2 Opening Keynote Address: How 'Proximity Medicines' Are Transforming Pharmacotherapy

- RAY DESHAIES, Former Senior Vice President of Global Research, Amgen
- Ray's talk will be taking place at 9:00 on Day 2.



## Interactive Sessions

Get up close and personal with industry trailblazers in our variety of roundtables and panel discussions. Hear firsthand how leaders are tackling big challenges in implementing novel technologies such as AI/ML, driving innovation, and shaping the future of drug development. Expect meaningful debates, bold ideas, and valuable insights you won't find in a typical presentation



## The Start Up Zone Program

Step into the spotlight at Discovery & Development US 2025's Start-Up Zone – a dynamic launchpad for 10+ cutting-edge start-ups in drug discovery and development. Pitch your vision, showcase your tech, and connect with key players driving innovation. From AI-driven discovery to lab automation and next-gen therapeutics, this is your stage to shine.

[Welcome](#)
[Benefits of Attending](#)
[Sponsors](#)
[Special Event Features](#)
[Agenda at a Glance](#)
[Featured Speakers: Discovery](#)
[Featured Speakers: Formulation](#)
[All Speakers](#)
[Full Programme: Day One](#)
[Full Programme: Day Two](#)
[Venue Information](#)
[Book Now](#)



# Program Agenda at a Glance

**Explore Discovery & Development US 2025:** North America’s leading event for drug discovery, preclinical development and formulation returns in October 2025, uniting experts in both small molecule and biologics drug development to deliver first-in-class drugs at pace.

	Day One		Day Two	
Cross-Programme Features	Opening Keynote Address Interactive Networking Breaks: Poster Presentations & 1-2-1 Meetings Networking Drinks Reception Garden Party		Opening Keynote Address Breakfast Roundtables Interactive Networking Breaks: Poster Presentations & 1-2-1 Meetings	
Drug Discovery Program	Track 1	Novel Target ID for Small & Large Molecules	Track 1	Part 1: DMPK, Pharmacology & Safety Part 2: Hit Identification, Optimization & Screening
	Track 2	Medicinal & AI-Guided Computational Chemistry	Track 2	Part 1: Implementing Lab Automation & Digitization Part 2: Degraders & Molecular Glues
Formulation & Delivery Program	Track 3	Small Molecule Formulation	Track 3	Large Molecule Formulation
	Track 4	Part 1: Large Molecule Delivery & RNA Design Part 2: Large Molecule Formulation & RNA Design	Track 4	Part 1: Small Molecule Delivery Part 2: Large Molecule & RNA Delivery
Start Up Zone	Afternoon: Start-Up Zone Presentations			



Join leading scientific experts through our annual **Discovery and Automation & Robotics** programs, addressing critical **strategies**, scientific breakthroughs and the latest technological advancements in novel modalities & computational tools, new case studies on PROTACs & molecular glues and the utilization of AI, robotics & automation in early R&D.

**VPs, Directors & Senior Managers** from leading pharma & biotech companies and research institutions in the following fields and more:

- PROTACs
- Medicinal Chemistry
- Lead Generation
- Screening
- Small Molecule Discovery
- AI/ML
- Lab Automation
- Digital Transformation
- DMPK
- Molecular Glues

**Formal and informal meeting opportunities** offer delegates the chance to discuss key solutions with leading service providers. Formal 1:1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated networking breaks covering:

- Library Optimisation
- Screening Technologies
- Target Validation
- Organoid Discovery
- Protein Degradation Tools
- Automation
- Computational Tools
- Animal Models
- Inhibitor Discovery
- AI/ML

## Day One

### Day 1 Track 1: Novel Target ID for Small & Large Molecules

- Technological advancements for the discovery of novel new targets
- New paradigms beyond the rule of five
- AI to unblock drug discovery, drug repurposing and target validation
- Complementary use of genomic & proteomic technologies with AI
- 3D organoids to pursue 'undruggable' targets
- How can we streamline translation of basic scientific findings into human applications
- Disease-centric biologic insights and dealing with increasingly complex target biology
- New modalities that go after the target identification phase: ADCs, cell therapies, bispecific antibodies
- Validating novel biomarkers to improve success in early drug development

### Track 2: Medicinal & AI-Guided Computational Chemistry

- New approaches in computer-aided drug design
- Quantum mechanics in drug discovery
- Fragment & structure-based drug design, including Cryo-EM applications
- Biocatalysis for pharmaceutical synthesis & drug discovery
- Utilising high-quality chemical probes
- Progressing 'intractable targets' from a medicinal chemistry & DMPK perspective

## Day Two

### Track 1:

#### Part 1: DMPK, Pharmacology & Safety

- Predicting & Measuring PK/PD, including computational models
- Novel models for ADME-Tox research & disease modelling – including organ-on-a-chip, organoids, iPSC-derived cells and humanized mouse models
- Development of animal efficacy models
- Safety assessment & safety pharmacology
- Human dose prediction

#### Part 2: Hit Identification, Optimization & Screening

- Molecular target-based screening
- Phenotypic screening
- Affinity/binding assays for hit ID, including mass spectrometry, biophysical approaches, DNA-encoded libraries, high content imaging & computational screening

### Track 2:

#### Part 1: Implementing Lab Automation & Digitization

- Automating laboratory workflows through discovery & development to improve productivity
  - Lab robotics & tools for drug discovery
- Digital transformation & digitization strategies

#### Part 2: Degraders & Molecular Glues

- Discovery & optimization of novel degraders using:
  - » Screening technologies
  - » Proteomics & mass spec
  - » Biophysical techniques
- New technologies & platforms for glue discovery
- PROTACs & targeted protein degradation
- Exploring new degradation pathways & modalities
- Rational design & mechanistic understanding of molecular glues



**Join world-leading experts in drug product development and delivery for this in-person meeting on the West Coast's scientific hub, San Diego.** You'll learn about the latest advancements in the formulation of large and small molecule-based drugs, developments in RNA and explore the innovations in the delivery of complex and challenging therapeutics.

**VPs, Directors & Senior Managers** from leading pharma & biotech companies and research institutions in the following fields and more:

- Formulation Science
- Drug Delivery
- Bioanalysis
- Device Development
- RNA Delivery
- Pharmaceuticals
- Pharmaceutical Sciences
- Nanomedicine
- Drug Formulation
- Sustainable Formulation

**Formal and informal meeting opportunities** offer delegates the chance to discuss key solutions with leading service providers. Formal 1:1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated networking breaks covering:

- Contract Development
- Characterization Tools
- Raw Materials
- Analytical Services
- Solubility & Stability Testing
- Dosage Forms
- Delivery Devices
- Formulation Development
- Quality Control
- Controlled Release

## Day One

### Track 3: Small Molecule Formulation

- Overcoming challenges in small molecule drug formulation and delivery including non-oral routes
- Recent advances to improve bioavailability: permeability, solubility
- Digitalization and automation of processes: AI/ML, in-silico modelling

### Track 4: Part 1: Large Molecule Delivery & RNA Design

- Moving beyond injectable delivery of biologics including inhalation
- Overcoming oral delivery challenges
- Innovative technologies developing personalized drug delivery systems
- Novel strategies for RNA design
- Harnessing inherent potency of peptides with long-acting injectables and depositions

### Track 4 Part 2: Large Molecule Formulation & RNA Design

- Overcoming challenges in RNA delivery
- Lipid nanoparticles to deliver RNA

## Day Two

### Track 3: Large Molecule Formulation

- Innovative formulation strategies for ADCs, cell & gene therapies, peptides and more
- Overcoming challenges in large molecule drug formulation
- Formulating therapies for pre-filled syringe delivery
- Optimizing high dosage biologics

### Track 4: Part 1: Small Molecule Delivery

- Oral dosage form improvement
- Novel routes of administration for small molecules: pulmonary, transdermal, topical, ocular, nasal
- Patient-friendly delivery and dosage forms
- Challenges of delivering sustainability

### Track 4: Part 2: Large Molecule & RNA Delivery

- Lipid nanoparticles to deliver biologics
- Pre-filled syringes
- Use cases of utilizing viral and nonviral delivery modalities
- Overcoming challenges in RNA delivery
- Advanced techniques for delivery beyond the liver

## ★ DR. RAY DESHAIES

Former Senior Vice President of Global Research, Amgen

Dr. Deshaies received the 25th Jacob and Louise Gabbay Award in Biotechnology and Medicine for his pioneering work on PROTACs (proteolysis targeting chimeras), a novel approach in targeted protein degradation.

## ★ DR. RICK EWING

Vice President, Head of Chemistry, Rapafusyn Pharmaceuticals

Dr. Ewing was honored with the 2023 American Chemical Society (ACS) Philadelphia Section Award, recognizing his distinguished career in medicinal chemistry.

## ★ DR. ROBERT FREMEAU

Founder & Chief Executive Officer, BrainStorm Therapeutics

Dr. Fremeau serves as the Principal Investigator for a National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I award, focusing on developing a novel Parkinson's disease drug discovery platform.

## ★ DR. BETH HOFFMAN

President & Chief Executive Officer, Origami Therapeutics, Inc.

Earlier in her career, Dr. Hoffman was awarded the Anna-Monika Foundation Prize for Advancement in Depression Research and an NSF Pre-doctoral Fellowship.

Click Below to Preview our  
Award Winning Speaker's  
Presentations



RAY ROBERT RICK BETH



\*Left to right  
Dr. Beth Hoffman, Dr. Rick Ewing, Dr. Ray Deshaies, Dr. Robert Fremeau



## Shaping Drug Development Now

**ERIC MUNSON,**

Professor, Purdue University

IPEC Americas Foundation: Ralph Shangraw Memorial  
Award 2020

**ANDREW GEALL,**

Co-Founder & Chief Development Officer, Replicate  
Bioscience

**BINDHU RAYAPROLU,**

Director, Research & Development, Regeneron

**MARIA WINZELL,**

Senior Director Drug Development, Camurus

**DIMITRIOS ZISOULIS,**

Head of RNA Therapeutics,  
Janssen Pharmaceutical Companies of Johnson &  
Johnson

Click Below to Preview our Featured  
Speaker's Presentations



ERIC ANDREW BINDHU MARIA DIMITRIOS



## STEVE TURNER

Chief Executive Officer, Pangio Biosystems & Former Founding Chief Executive Officer, PacBio

## RAY DESHAIES

Former Senior Vice President of Global Research, Amgen

## SHAH NAWAZ

Former Vice President, Head of Technology & Digital Transformation, Regeneron

## ROBERT FREMEAUX

Founder & Chief Executive Officer, BrainStorm Therapeutics

## BETH HOFFMAN

President & Chief Executive Officer, Origami Therapeutics, Inc.

## SAM SINAI

Co-Founder, Vice President, & Head of Machine Learning, Dyno Therapeutics

## RICK EWING

Vice President, Head of Chemistry, Rapafusyn Pharmaceuticals

## STEFANO ZANOTTI

Senior Vice President, Neuromuscular Research, Dyne Therapeutics

## DAVID BUCKLER

Executive Director – Research Program Management, Regeneron

## PRASHI JAIN

Director, Drug Discovery, Iterion Therapeutics

## KAUSHEEK NANDY

Digital Transformation Director – Research, Boehringer Ingelheim

## SHANTHI NAGARAJAN

Director, Eli Lilly

## JOSH BAUGHMAN

Scientific Director, Bristol Myers Squibb

## LEI JIA

Associate Director, Drug Discovery Data Science, Johnson & Johnson

## SURENDRA NAYAK

Scientific Associate Director, Bristol Myers Squibb

## ABHINAV SHARMA

Translational Human Models Lead, Dermatology/Immunology Discovery, AbbVie

## FABIEN VINCENT

Consultant, Former Pharmacology Lab Head, Pfizer

## PHIL COX

Research Fellow, Discovery Research, AbbVie

## JEAN GE

Patent Attorney, Wolf Greenfield

## SHUANGWEI LI

Director of Toxicology, Calibr-Skaggs Institute for Innovative Medicines

## KATHERIN PATSCH

Director, Drug Discovery, Ellison Medical Institute

## TOBIAS RAABE

Director, Translational Genome Editing Laboratory, Perelman School of Medicine, University of Pennsylvania

## JOSEPH WU

Professor & Director, Stanford Cardiovascular Institute & Co-Founder, Greenstone Biosciences

## NAGENDRA CHEMUTURI

Senior Director, ADME, Eli Lilly

## YUE WEBSTER

Vice President, Model Driven Drug Discovery Platforms, Eli Lilly

## PEGGY THOMPSON

Vice President, Head of Biology, Plexium

## KISHORE PASIKANTI

Senior Director, DMPK, Grünenthal Group

## DAVID LOYND

Chief Executive Officer, EnduRx

## PETER HEIFETZ

Chief Executive Officer, Orpro Therapeutics

## ANDREW GEALL

Co-Founder & Chief Development Officer, Replicate Bioscience

## CRAIG BEHNKE

Executive Vice President, Production & Development, Lumen Bioscience

## SEAN SULLIVAN

Vice President of Technology Innovation & Development, Arcturus Therapeutics

## MARIA WINZELL

Senior Director Drug Development, Camurus

## BINDHU RAYAPROLU

Director, Research & Development, Regeneron

## JAMIE TSUNG

Director, Alnylam Pharmaceuticals

## STEPHEN FRAMIL

Corporate Global Head of Accessibility, Merck





SPEAKERS ACROSS ALL PROGRAMS

# Discovery & Development US

## DIMITRIOS ZISOULIS

Head of RNA Therapeutics, Janssen  
Pharmaceutical Companies of  
Johnson & Johnson

## SUNITA YADAV

Associate Director, Novartis

## SAYONI RAY

Principal Scientist, Janssen Pharmaceutical  
Companies of Johnson & Johnson

## JITENDRA KUMAR

Lead Scientist, Chemistry & Process  
Development, Entos Pharmaceuticals

## ERIC MUNSON

Professor, Purdue University

## ENRICO ZAMBELLI

Sustainable Formulations Unit Manager, Chiesi

## ELENA LIANG

Principal Research Scientist, AbbVie

## ASHLEY DAVALOS

Assistant Director, Ionis

## KALPITA MEHTA

Principal Combination Production & Medical  
Device Expert, Hikma

## JACK ROGERS

Director of Neurochemistry, Harvard University

## CATHERINE CAHILL

Assistant Professor, Harvard Medical School

## SEVERIN SCHNEEBELI

Associate Professor, Purdue University

## ANISHA DSOUZA

Research Fellow, Massachusetts Eye and Ear  
Infirmary, Harvard Medical School

## SHILPA THOSAR

Former Executive Director, Cara Therapeutics

## RAMESH KASHI

Former Senior Scientific Director, Bristol Myers  
Squibb

## MARK ECCLESTON

Chief Executive Officer, ValiRx

## VIVEK GUPTA

Associate Professor, St. John's University

## BROCHURE CONTENTS

Welcome

Benefits of  
Attending

Sponsors

Special  
Event  
Features

Agenda at  
a Glance

Featured  
Speakers:  
Discovery

Featured  
Speakers:  
Formulation

All Speakers

Full  
Programme:  
Day One

Full  
Programme:  
Day Two

Venue  
Information

Book Now

LinkedIn  
@OGConferences

08:50

09:00

09:35


10:00 - 11:00

Day One | October 2 2025

Welcome & Keynote Address


Coral 5

Oxford Global’s Welcome Address By Eszter Sutowski Nagy, Senior Production Director

 **OPENING KEYNOTE ADDRESS & Q&A IN CORAL 5**

**The Single-Molecule Revolution Makes Landfall In Drug Discovery: Where We Are Now & What’s To Come**

STEVE TURNER, Chief Executive Officer, **Pangio Biosystems** & Former Founding Chief Executive Officer, **PacBio**



Q&A session & transition time between conference rooms

DRUG DISCOVERY PROGRAM		FORMULATION & DELIVERY PROGRAM	
NOVEL TARGET ID FOR SMALL & LARGE MOLECULES	MEDICINAL & AI-GUIDED COMPUTATIONAL CHEMISTRY	SMALL MOLECULE FORMULATION	LARGE MOLECULE DELIVERY & RNA DESIGN
CORAL 1	CORAL 2	SEAGLASS	CORAL 3
Morning Track Chair: ABHINAV SHARMA, Translational Human Models Lead, Dermatology/Immunology Discovery, AbbVie	Morning Track Chair TBA	Morning Track Chair TBA	Morning Track Chair: ERIC MUNSON, Professor, Purdue University
Track Keynote Address: Utilizing Human Genetics Technology For Antibody Discovery	Track Keynote Address: Targeting TBL1: Molecular & Computational Strategies To Modulate Complex Protein Interactions In Wnt Signaling <ul style="list-style-type: none"><li>•This talk highlights mechanistic studies describing the inhibition of TBL1 by tegavivint and the development of second-generation small-molecule inhibitors using structural biology and predictive computational approaches</li><li>•Tegavivint is a small-molecule inhibitor of TBL1 that is currently in clinical trials for multiple oncology indications. Using in silico predictive modeling, we have identified a series of novel small molecules that bind to TBL1 and inhibit Wnt signaling. We will present novel strategies employed to identify these compounds and discuss the structural studies that guided lead optimization against this complex protein target</li></ul>	Track Keynote Address: Strategies For RNA Therapy For AD/PD With Implications For Treating SARS-CoV-2 <p>We reported that the broad-acting Alzheimer’s disease clinical drug Posiphen inhibited translation of the amyloid precursor protein as well as the mRNA encoding alpha-synuclein, the major culprit protein of Parkinson’s disease &amp; the Huntingtin protein. However, our new pipeline of translation blockers seeks to prevent neurodegeneration with potent drugs that interfere at higher selectivity with these 5’untranslated regions of the neurodegenerative disease-associated transcripts, i.e. the APP/ amyloid of AD and PD specific asyn. Recently, we discovered a line of therapy to inhibit APP translation linked to providing RNA-directed inhibitory actions to limit COVID by lowering the translation rates of the replicase in SARS-CoV-2.</p> CATHERINE CAHILL, Assistant Professor, & JACK ROGERS, Director of Neurochemistry, Harvard University	Track Keynote Address: Navigating the Next Frontier: Industry Insights Into Emerging Trends In Biologics Delivery <p>Biologics, which include complex molecules like proteins, monoclonal antibodies, and gene therapies, are revolutionizing modern medicine. As the industry continues to innovate, biologics delivery systems are evolving to meet the growing demand for precision, efficiency, and patient-centric care. This presentation explores the emerging trends shaping the future of biologics delivery, focusing on cutting-edge advancements, challenges, and opportunities.</p> BINDHU RAYAPROLU, Director, Research & Development, Regeneron
DAVID BUCKLER, Executive Director – Research Program Management, Regeneron			
MORNING BREAK & REFRESHMENTS			
1-2-1 Meetings x3		Poster Displays	

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now



Day One | October 2 2025

DRUG DISCOVERY PROGRAM

FORMULATION & DELIVERY PROGRAM

NOVEL TARGET ID FOR SMALL & LARGE MOLECULES

MEDICINAL & AI-GUIDED COMPUTATIONAL CHEMISTRY

SMALL MOLECULE FORMULATION

LARGE MOLECULE DELIVERY & RNA DESIGN

CORAL 1

CORAL 2

SEAGLASS

CORAL 3

Solution Provider Presentation

Solution Provider Presentation

Solution Provider Presentation

Solution Provider Presentation

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)



MICHAEL BELLUCCI, Senior Director of R&D, Xtalpi



Senior Representative, Almac



Senior Representative, Pfanstiehl

Q&A session & transition time between conference rooms

AI-Powered Human Brain Organoid Platform To Transform CNS Drug Discovery

- Pioneering a new paradigm in CNS drug discovery
- Integrating patient-derived brain organoids with AI to accelerate therapeutic discovery
- Building AI foundation models to map disease-relevant gene networks
- Deploying biomarker-based screening to identify efficacious compounds in human brain disease models at the outset of drug discovery
- Delivering a scalable platform with broad applicability across complex neurodevelopmental and neurodegenerative disorders

ROBERT FREMEAU, Founder & Chief Executive Officer, BrainStorm Therapeutics

Chemical Space Generation, Exploration, And Visualization

The number of theoretically possible drug-like molecules is vast and estimated to be >1060. Currently it is not practically feasible to enumerate such vast numbers, however it is possible to use abbreviated methods that encode the entirety of space using reaction SMARTS and associated monomer building blocks. This talk will focus on how we used such a method to generate and explore Nebula, AbbVie's UL chemical space.

PHIL COX, Research Fellow, Discovery Research, AbbVie

How Digital Accessibility Is Critical For Digital Health Solutions

- Personalized drug delivery systems
- Digital accessibility
- Formulation considerations for digital health solutions

STEPHEN FRAMIL, Corporate Global Head of Accessibility, Merck

Polymeric Carriers Enabling Multi-Route Non-Invasive Delivery Of Large Therapeutic Molecules

- Understand the key challenges and physiological barriers associated with non-invasive delivery of large molecule therapeutics
- Explore the design principles and material considerations behind engineering multifunctional carriers
- Evaluate preclinical data demonstrating the pharmacokinetic, biodistribution, and therapeutic performance of these engineered carriers

VIVEK GUPTA, Associate Professor, St. John's University

Q&A session & transition time between conference rooms

Gold Solution Provider Presentation

Solution Provider Presentation

Solution Provider Presentation

Solution Provider Presentation

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)



Senior Representative, Chemaxon



Senior Representative, Aprecia



Senior Representative, Nof Corporation

LUNCH BREAK



1-2-1 Meetings x4



Poster Displays



BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

LinkedIn

@OGConferences

Day One | October 2 2025

DRUG DISCOVERY PROGRAM

NOVEL TARGET ID FOR SMALL & LARGE MOLECULES  
CORAL 1

Afternoon Track Chair: TOBIAS RAABE, Director, University of Pennsylvania


Gold Solution Provider Presentation

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

MEDICINAL & AI-GUIDED COMPUTATIONAL CHEMISTRY  
CORAL 2

Afternoon Track Chair TBA

Solution Provider Presentation




Senior Representative, **Optibrium**

FORMULATION & DELIVERY PROGRAM

SMALL MOLECULE FORMULATION  
SEAGLASS

Afternoon Track Chair TBA

Solution Provider Presentation




Senior Representative, **Xtalpi**

LARGE MOLECULE DELIVERY & RNA DESIGN  
CORAL 3

Afternoon Track Chair: ERIC MUNSON, Professor, Purdue University

Small Particles, Big Impact: Maximizing Therapeutic Impact Through Nanoparticle-Enabled Delivery

Learn how key drug delivery challenges such as targeting, bioavailability, and circulation time can be overcome through nanoparticle-enabled formulations.



JESS WIDMAN, Senior Product Development Scientist, **Fortis Life Sciences**

Q&A session & transition time between conference rooms

The FORCETM Platform Delivers Functional Improvement In DM1 & DMD

STEFANO ZANOTTI, Senior Vice President, Neuromuscular Research, **Dyne Therapeutics**

Utilizing AI/ML Models To Optimize Screening Techniques

SAM SINAI, Co-Founder, Vice President & Head of Machine Learning, **Dyno Therapeutics**

Formulation Of CLX-001, A Next Generation Oncolytic Peptide For Cancer Therapy

- CLX001 – a novel oncolytic peptide
- Membrane-lytic peptide based intravenous nanotherapeutics
- Oncolytic peptides – synergistic agents for small molecule and Immunotherapy

MARK ECCLESTON, Chief Executive Officer, **ValiRx**

FAST Protein-Enabled Proteolipid Vehicles: A Novel Platform For Advanced Gene Therapy Delivery

- FAST protein integration into proteolipid vehicles (PLVs) enables efficient delivery of therapeutic DNA and RNA directly into target cell cytoplasm by overcoming endocytosis barriers
- FAST protein-enabled PLVs demonstrate broad biodistribution and low immunogenicity in animal models, maintaining sustained gene expression for extended periods without significant inflammatory responses
- The PLV platform, leveraging FAST proteins, offers a durable and versatile system capable of delivering large genetic payloads, including CRISPR-Cas9, with significant implications for future gene therapies

JITENDRA KUMAR, Lead Scientist, Chemistry & Process Development,, **Entos Pharmaceuticals**

Q&A session & transition time between conference rooms

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full Programme: Day One

Full Programme: Day Two













Venue Information

Book Now

Linked in

@OGConferences



Day One   October 2 2025				
DRUG DISCOVERY PROGRAM		FORMULATION & DELIVERY PROGRAM		
NOVEL TARGET ID FOR SMALL & LARGE MOLECULES CORAL 1	MEDICINAL & AI-GUIDED COMPUTATIONAL CHEMISTRY CORAL 2	SMALL MOLECULE FORMULATION SEAGLASS	LARGE MOLECULE FORMULATION & RNA DESIGN CORAL 3	
Solution Provider Presentation	Solution Provider Presentation	Solution Provider Presentation	Solution Provider Presentation	
14:25 <div></div> Senior Representative, Fronteo	<div></div> Senior Representative, Concept Life Sciences	<div></div> Senior Representative, Crystal Pharmatech	<div></div> Senior Representative, SP Scientific Products	
14:50 - 15:50 AFTERNOON BREAK				
<div></div> 1-2-1 Meetings x3 <div></div>		<div></div> Poster Displays <div></div>		
Solution Provider Presentation	Use Of Virtual Libraries To Accelerate Drug Discovery: A Case Study  The use of virtual libraries in Drug Discovery has shown increased popularity in recent years alongside the development of more powerful search and evaluation software. Here we will describe the design of the eMolecules/Synple Virtual libraries and a case study of its use in a drug discovery program.	Solution Provider Presentation	Solution Provider Presentation	
15:50 <div></div> Senior Representative, Collaborative Drug Discovery, Inc	<div></div> DAVID JAMES, Senior Vice President Scientific Business Development, eMolecules	<div></div> Senior Representative, BioDuro	<div></div> Senior Representative, Millipore Sigma	
Q&A session & transition time between conference rooms				

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

LinkedIn

@OGConferences

Day One | October 2 2025

DRUG DISCOVERY PROGRAM

FORMULATION & DELIVERY PROGRAM

NOVEL TARGET ID FOR SMALL & LARGE MOLECULES

START UP ZONE

SMALL MOLECULE FORMULATION

LARGE MOLECULE FORMULATION & RNA DESIGN

CORAL 1

CORAL 2

SEAGLASS

CORAL 3

Complex In Vitro Models For Drug Discovery & Development Of Immunological Disorders

INTERACTIVE

PANEL DISCUSSION:

The Status Of AI/ML In Drug Discovery: Where Are We And Where Are We Going?

- Examples of successful application / acceleration of discovery programmes using AI/ML
- Best practices
- Limitations & challenges

Panellists:

PHIL COX, Research Fellow, Discovery Research, **AbbVie**

MATTHEW SEGALL, Chief Executive Officer, **Optibrium**

KATHERIN PATSCH, Director, Drug Discovery, **Ellison Medical Institute**

INTERACTIVE

WORKSHOP:

Tides Analytical Development: Innovations In Oligonucleotides & Peptide Analysis & Delivery

Presentation 1: New Computational & Experimental Insight Into Oral Peptide Delivery With Permeation Enhancers

Oral peptide formulations improve patient compliance by eliminating injections, especially in early-stage disease where long-term adherence is crucial. Permeation enhancers have transformed oral delivery by enabling peptides to cross the intestinal barrier safely, allowing effective systemic absorption. Despite these advances, further refinement and understanding of enhancer mechanisms are needed. This presentation offers new insights into their function, supported by constant pH molecular dynamics simulations and experimental data from relevant model systems.

SEVERIN SCHNEEBELI, Associate Professor, **Purdue University**

Presentation 2: Universal Assay Determination Method For Antisense Oligonucleotides Via Slope Spectroscopy

Developed a universal assay method for antisense oligonucleotide (ASO) drug products using slope spectroscopy with the SoloVPE system, offering a simple, robust alternative for in-process control (IPC) of ASO concentration. The method was optimized across multiple parameters and validated for linearity, accuracy, precision, reproducibility, and robustness—with excellent performance across different ASO chemistries and formulations. The method proved transferable across sites (Ionis and CMOs), is independent of specific ASO attributes, and was recognized as a universal IPC assay platform for broad application in ASO drug product manufacturing.

ASHLEY DAVALOS, Assistant Director, **Ionis**

INTERACTIVE

WORKSHOP:

The Changing Landscapes Of RNA Design & Delivery

Presentation 1: Translation Of An Optimized Self-Replicating RNA (srRNA) Platform With An Expanded Clinical Therapeutic Index

- Demonstration that next generation srRNA vectors with optimized non-coding regions achieve protective immunity at doses up to 1,000,000-fold lower than conventional mRNA in preclinical models of influenza and rabies
- Phase I clinical data with RBI-4000, an improved srRNA vector encoding the rabies virus glycoprotein and encapsulated in a novel lipid nanoparticle. Demonstrating the high therapeutic index of next generation srRNA vectors and the feasibility of both low dose and single dose administration for vaccine applications
- Potential of srRNA for applications beyond vaccines

ANDREW GEALL, Co-Founder & Chief Development Officer, **Replicate Bioscience**

Presentation 2: Lipid Nanoparticle (LNP) Formulation & mRNA Manufacturing Development

- Development of an ionizable lipid library
- Drug product formulation development
- Optimization of drug substance manufacturing unit operations

SEAN SULLIVAN, Vice President of Technology Innovation & Development, **Arcturus Therapeutics**

Stem Cells, Genomics & AI For Drug Discovery

- Learn recent announcements of 'New Alternative Methodologies' by FDA, NIH and EPA
- Learn how stem cells, organoids, genomics & AI can be integrated for drug discovery

JOSEPH WU, Professor & Director, **Stanford Cardiovascular Institute** & Co-Founder, **Greenstone Biosciences**

Start Up Zone Presentations x2

Q&A session & transition time between conference rooms

Q&A session & transition time between conference rooms

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

LinkedIn

@OGConferences



DRUG DISCOVERY PROGRAM

FORMULATION & DELIVERY PROGRAM

NOVEL TARGET ID FOR SMALL & LARGE MOLECULES  
CORAL 1

START UP ZONE  
CORAL 2

SMALL MOLECULE FORMULATION  
SEAGLASS

LARGE MOLECULE FORMULATION & RNA DESIGN  
CORAL 3

**Lipid Nanoparticles Enable Efficient Cell Type Specific Gene Targeting In A Patient Liver - Derived Fibrosis Model**

- We developed a lipid nanoparticle-based platform that enables >80% gene targeting efficiency in non-dividing hepatocytes, cholangiocytes, myofibroblasts, and proinflammatory macrophages within a fully human 3D organoid model in just two days. This system supports cell type-specific knockdown, overexpression, or editing for multi-target liver fibrosis therapies
- Our modular, patient-derived organoid model allows parallel screening across diverse fibrotic liver diseases, including MASH, cholangiopathies, alcohol-related cirrhosis, and viral fibrosis

TOBIAS RAABE, Director, Translational Genome Editing Laboratory, Perelman School of Medicine,  
**University of Pennsylvania**

Start Up Zone Presentations  
(10 min) **Presentation 1: Si-Care Bio**



(10 min) **Presentation 2: Athens LifeTech Park**



**INTERACTIVE**

**WORKSHOP (CONT.): Tides Analytical Development: Innovations In Oligonucleotides & Peptide Analysis & Delivery**

**Panel Discussion: Exploring Alternative Route Of Tides Delivery**

- Oral delivery of peptides
- Nasal delivery
- Delivering oligos beyond the liver
- Pre-filled syringes
- Sustainability and stability considerations

**INTERACTIVE**

**WORKSHOP (CONT.): The Changing Landscapes Of RNA Design & Delivery**

**Panel Discussion: Novel Strategies For RNA Design & Delivery**

- RNA Interference (RNAi)
- microRNA
- Antisense Oligonucleotides
- circRNA

Q&A session & transition time between conference rooms

**INTERACTIVE**

**PANEL DISCUSSION: Advanced Tools & Tech For Drug Discovery**

- Making use of all the datasets
- New alternative methods

**Panellists:**

DAVID BUCKLER, Executive Director – Research Program Management, **Regeneron**  
SAM SINAI, Co-Founder, Vie President, & Head of Machine Learning, **Dyno Therapeutics**  
JOSEPH WU, Professor & Director, **Stanford Cardiovascular Institute** & Co-Founder, **Greenstone Biosciences**  
ABHINAV SHARMA, Translational Human Models Lead, Dermatology/Immunology Discovery, **AbbVie**

(10 min) **Presentation 1: Insilico Prediction Of In-Vivo Efficacy At The Drug Design Stage**



(10 min) **Presentation 2: Ontologic**



**Moderator:** ERIC MUNSON, Professor, Purdue University

**Panellists:**

KALPITA MEHTA, Principal Combination Production & Medical Device Expert, **Hikma**  
ASHLEY DAVALOS, Assistant Director, **Ionis**  
SEVERIN SCHNEEBELI, Associate Professor, **Purdue University**  
SAYONI RAY, Principal Scientist, **Janssen Pharmaceutical Companies of Johnson & Johnson**

**Moderator:** SUNITA YADAV, Associate Director, **Novartis**

**Panellists:**

DIMITRIOS ZISOULIS, Head of RNA Therapeutics, **Janssen Pharmaceutical Companies of Johnson & Johnson**  
ANDREW GEALL, Co-Founder & Chief Development Officer, **Replicate Bioscience**  
SEAN SULLIVAN, Vice President of Technology Innovation & Development, **Arcturus Therapeutics**  
JAMIE TSUNG, Director, **Alnylam Pharmaceuticals**

Q&A session & transition time between conference rooms

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full Programme: Day One


Full Programme: Day Two

Venue Information

Book Now

LinkedIn

@OGConferences

Day One   October 2 2025			
DRUG DISCOVERY PROGRAM		FORMULATION & DELIVERY PROGRAM	
NOVEL TARGET ID FOR SMALL & LARGE MOLECULES CORAL 1	START UP ZONE CORAL 2	SMALL MOLECULE FORMULATION SEAGLASS	LARGE MOLECULE FORMULATION & RNA DESIGN CORAL 3
<div>INTERACTIVE</div> <div>PANEL DISCUSSION: Advanced Tools &amp; Tech For Drug Discovery</div> <div><div>• Making use of all the datasets</div><div>• New alternative methods</div></div> <div>17:55</div> <div><div>Panellists:</div><div>DAVID BUCKLER, Executive Director – Research Program Management, <b>Regeneron</b></div><div>SAM SINAI, Co-Founder, Head of Machine Learning, <b>Dyno Therapeutics</b></div><div>JOSEPH WU, Professor &amp; Director, <b>Stanford Cardiovascular Institute</b> &amp; Co-Founder, <b>Greenstone Biosciences</b></div><div>ABHINAV SHARMA, Translational Human Models Lead, Dermatology/Immunology Discovery, <b>AbbVie</b></div></div>	<div>(10 min) Presentation 1: Epigenetic Therapies For Next-Generation Pain Therapeutics &amp; Beyond</div> <div>FERNANDO ALEMAN, Co-Founder &amp; Chief Scientific Officer, <b>Navega Therapeutics</b></div> <div></div>	<div>INTERACTIVE</div> <div>PANEL DISCUSSION: Digitization &amp; Automation Of Formulation Processes</div> <div><div>• Developments with AI within formulation</div><div>• Utilising the latest technology</div><div>• AI/ML for personalized formulation</div></div> <div><div>Moderator:</div><div>SHILPA THOSAR, Former Executive Director, <b>Cara Therapeutics</b></div><div>Panellist:</div><div>STEPHEN FRAMIL, Corporate Global Head of Accessibility, <b>Merck</b></div><div>VIVEK GUPTA, Associate Professor, <b>St. John’s University</b></div></div>	<div>Attendees are welcome to join co-located sessions</div>
<div>18:20</div> <div>Grab a drink &amp; make your way to the Visionary Voices Stage for the end of day summaries</div>			
CLOSE OF DAY ONE			
Innovations & Breakthroughs Under the Stars Garden Party at Eventide Gardens, Sheraton San Diego		Welcome Address by Dr Rick Ewing, Vice President, Head of Chemistry, Rapafusyn Pharmaceuticals	

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

Linked in

@OGConferences



Day Two | October 3 2025

Morning Roundtables with Continental Breakfast In Coral Foyer

08:30

ROUNDTABLE DISCUSSION 1:

INTERACTIVE

IP Considerations In Early Discovery & Development

- Establishing effective IP infrastructure
- Crafting a coherent IP strategy that aligns with early discovery and development activities
- Building a “diligence ready” IP portfolio

Moderator: JEAN GE, Patent Attorney, Wolf Greenfield

ROUNDTABLE DISCUSSION 2:

INTERACTIVE

Best Practice Data Management Strategies In The Lab

- Strategies for data management in labs of the future
- Considerations & challenges

Moderator: YUE WEBSTER, Vice President, Model Driven Drug Discovery Platforms, Eli Lilly

ROUNDTABLE DISCUSSION 3:

INTERACTIVE

From Drug Product Development To Overcoming Regulatory Hurdles

- Regulatory lifecycle
- Aligning product development strategies with regulatory expectations

Moderator: SHILPA THOSAR, Former Executive Director, Cara Therapeutics

ROUNDTABLE DISCUSSION 4:

INTERACTIVE

LNP Formulation Development Of RNA & DNA

- Tailoring LNPs for different administration routes
- Optimizing formulations

Moderator: SAYONI RAY, Principal Scientist, Janssen Pharmaceutical Companies of Johnson & Johnson

Q&A session & transition time between conference rooms


09:00

KEYNOTE ADDRESS IN CORAL 5:



How ‘Proximity Medicines’ Are Transforming Pharmacotherapy

Multispecific medicines - both large and small molecule - are on the ascendancy. Half of the 72 FDA-approved multispecific drugs have gained approval since 2020, and from 2022-24, multispecifics accounted for 1/6th of FDA approvals. Among the different categories of multispecific drugs, proximity medicines are of particular interest. These medicines typically work by either localizing the therapeutic molecule or recruiting a regulatory mechanism in the body to modulate the target. I will discuss the advantages conferred by multispecificity with particular emphasis on proximity medicines, and will describe a category of proximity medicines – LOCKTACS – that work by stabilizing a pre-existing complex.

RAY DESHAIES, Former Senior Vice President of Global Research, Amgen



Q&A session & transition time between conference rooms

DRUG DISCOVERY PROGRAM		AUTOMATION & ROBOTICS PROGRAM	FORMULATION & DELIVERY PROGRAM	
DMPK, PHARMACOLOGY & SAFETY		IMPLEMENTING LAB AUTOMATION & DIGITIZATION	LARGE MOLECULE FORMULATION	SMALL MOLECULE DELIVERY
CORAL 1		CORAL 2	SEAGLASS	CORAL 3
Track Chair: SHUANGWEI LI, Director of Toxicology, Calibr-Skaggs Institute for Innovative Medicines		Morning Track Chair TBA	Morning Track Chair TBA	Morning Track Chair TBA
Solution Provider Presentation		Platinum/Gold Solution Provider Presentation	<div>INTERACTIVE</div> <div>SPONSORED WORKSHOP:</div> <div>Tackling CMC &amp; Manufacturing Challenges Of Complex LNP-Based Biopharmaceuticals For Oncological, Gene Editing &amp; Vaccine Applications</div> <div>SARTORIUS</div>	Solution Provider Presentation
<div></div> <div>Senior Representative, Optibrium</div>		<div>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></div>		<div></div> <div>Senior Representative, Sever Pharma Solutions</div>
Q&A session & transition time between conference rooms			Q&A session & transition time between conference rooms	

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation











All Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

Day Two   October 3 2025						
DRUG DISCOVERY PROGRAM		AUTOMATION & ROBOTICS PROGRAM	FORMULATION & DELIVERY PROGRAM			
DMPK, PHARMACOLOGY & SAFETY CORAL 1	IMPLEMENTING LAB AUTOMATION & DIGITIZATION CORAL 2	LARGE MOLECULE FORMULATION SEAGLASS	SMALL MOLECULE DELIVERY CORAL 3			
<p><b>How Close Are We? The Evolving Science of Human PK Prediction</b></p> <p>This talk will explore the current landscape of human pharmacokinetic (PK) prediction, focusing on our ability to estimate clearance, volume of distribution, and oral bioavailability. We'll also examine a case study addressing non-linearity in PK and its impact on first-in-human dose selection—highlighting practical strategies, limitations, and evolving methodologies in human PK predictions.</p> <p>KISHORE PASIKANTI, Senior Director, DMPK, Grünenthal</p>	<p><b>Automated, Integrated Wet Lab &amp; Digital Platform</b></p> <p>This talk outlines Boehringer Ingelheim's strategic initiatives in digital and lab automation in the large molecule research space. It highlights investments in automation systems, digital integration, and lab orchestration to enhance biotherapeutics research, improve efficiency, and drive innovation at the Biotherapeutics department.</p> <p>KAUSHEEK NANDY, Digital Transformation Director – Research, Boehringer Ingelheim</p>	<p><b>INTERACTIVE</b></p> <p><i>SPONSORED WORKSHOP:</i></p> <p><b>Tackling CMC &amp; Manufacturing Challenges Of Complex LNP-Based Biopharmaceuticals For Oncological, Gene Editing &amp; Vaccine Applications</b></p> <p>SARTORIUS</p>	<p><b>Formulation Considerations For Polymeric Implants</b></p> <p>ELENA LIANG, Principal Research Scientist, AbbVie</p>			
Q&A session & transition time between conference rooms			Q&A session & transition time between conference rooms			
<p><b>Solution Provider Presentation</b></p> <p> <small>is now part of</small> </p> <p>Senior Representative, Hub Organoids</p>	<p><b>Solution Provider Presentation</b></p> <p></p> <p>Senior Representative, Brooks Automation</p>		<p><b>Solution Provider Presentation</b></p> <p></p> <p>Senior Representative, Seran</p>			
10:50 - 11:50						
<p> 1-2-1 Meetings x3 </p>					<p> Poster Displays </p>	
<p><b>Bronze Solution Provider Presentation</b></p> <p>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></p>	<p><b>Bronze Solution Provider Presentation</b></p> <p>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></p>	<p><b>Solution Provider Presentation</b></p> <p></p> <p>Senior Representative, Unchained Labs</p>	<p><b>Solution Provider Presentation</b></p> <p></p> <p>Senior Representative, Lubrizol</p>			
11:45						
Q&A session & transition time between conference rooms						

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full Programme: Day One

Full Programme: Day Two





Venue Information

Book Now

Linked in

@OGConferences



Day Two   October 3 2025				
DRUG DISCOVERY PROGRAM		FORMULATION & DELIVERY PROGRAM		
DMPK, PHARMACOLOGY & SAFETY CORAL 1	IMPLEMENTING LAB AUTOMATION & DIGITIZATION CORAL 2	LARGE MOLECULE FORMULATION SEAGLASS	LARGE MOLECULE & RNA DELIVERY CORAL 3	
<div>12:10</div> <div><b>Toxicology In Small Molecule Drug Discovery: From Target Safety Assessment To IND</b> Overview of the critical role toxicology plays in small molecule drug discovery, from early target safety assessment through IND-enabling studies Key strategies for identifying, characterizing, and mitigating safety risks during candidate selection and lead optimization Practical guidance on designing and timing toxicology studies to align with regulatory expectations and support successful IND submissions.  SHUANGWEI LI, Director of Toxicology, <b>Calibr-Skaggs Institute for Innovative Medicines</b></div>	<div><b>Bridging The Gap Between Automation, Digitalization, &amp; Innovation</b>          SHAH NAWAZ, Former Vice President, Head of Technology &amp; Digital Transformation, <b>Regeneron</b></div>	<div><b>Transforming Short-Acting Peptides Into Long-Acting Using Liquid Lipid Depot Formulations</b> • Presentation of the liquid lipid depot formulation technology – FluidCrystal® • Small volume, ready-to-use formulations for improved compliance and better efficacy • Examples of a variety of peptide formulations with extended half-lives with clinical data  MARIA WINZELL, Senior Director Drug Development, <b>Camurus</b></div>	<div><b>Sustainable Inhalation Devices – The Challenges Of Meeting Net Zero Global Emissions</b> • The transition to low global warming potential propellants in metered dose inhalers is essential for reducing the environmental impact of pharmaceutical aerosols • This presentation provides a technical overview of the challenges and strategies to address the change and significantly reducing the carbon foot print of MDIs  ENRICO ZAMBELLI, Sustainable Formulation Project Unit Manager, <b>Chiesi</b></div>	
Q&A session & transition time between conference rooms				
<div>12:35</div> <div><b>Bronze Solution Provider Presentation</b>  <div>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></div></div>	<div><b>Bronze Solution Provider Presentation</b>  <div>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></div></div>	<div><b>Bronze Solution Provider Presentation</b>  <div>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></div></div>	<div><b>Bronze Solution Provider Presentation</b>  <div>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></div></div>	
<div>13:00 - 14:00</div> <div><div> 1-2-1 Meetings x3 </div><div> Poster Displays </div></div>				

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

Linked In

@OGConferences

Day Two | October 3 2025

DRUG DISCOVERY PROGRAM

DMPK, PHARMACOLOGY & SAFETY

CORAL 1

DEGRADERS & MOLECULAR GLUES

CORAL 2

FORMULATION & DELIVERY PROGRAM

LARGE MOLECULE FORMULATION

SEAGLASS

LARGE MOLECULE & RNA DELIVERY

CORAL 3

Afternoon Track Chair:  
KISHORE PASIKANTI, Senior Director, DMPK, Grünenthal

Novel Models For ADME-Tox Research

INTERACTIVE

PANEL DISCUSSION:  
Successful Human Dose Prediction Across Modalities – Considerations & Challenges

•Optimization of small molecule compounds

•Traditional vs novel modalities

•Ensuring quality PK predictions

Panellists:

KISHORE PASIKANTI, Senior Director, DMPK, Grünenthal

SENIOR REPRESENTATIVE, Chemaxon

NAGENDRA CHEMUTURI, Senior Director, ADME, Eli Lilly

Afternoon Track Chair:  
DAVID BUCKLER, Executive Director, Program Management, Regeneron

RapaGlue™: A Novel Non-Degrading Molecular Glue Modality For Unlocking The Hard To Drug Proteome

Rapafuysn’s platform of non-degrading molecular glues is uniquely positioned to target intracellular proteins and the cytosolic side of transmembrane proteins unlocking the hard to drug proteome. The company’s platform of RapaGlue’s takes advantage of the cytosolic residing FKBP12 to form ternary complexes with disease target proteins. The presentation will describe successful hit campaign highlighting our progress in inhibiting the GTPase, GSTP1 a target for ferroptosis.

RICK EWING, Vice President, Head of Chemistry, Rapafusyn Pharmaceuticals

Q&A session & transition time between conference rooms

Afternoon Track Chair TBA

Solving Key Function & Formulation Challenges To Enable Development Of A Novel First In Class Thioredoxin-Based Therapeutic

•Thioredoxin is a previously unexploited secreted stress-protectant protein family with anti-inflammatory, anti-oxidative & ferroptosis-inhibiting activity

•Thioredoxin protects both normal & cancer cells & has demonstrated poor pharmacology with rapid clearance & an association with chemoresistance during cancer treatment

•Thioredoxin ORP100S has been designed & formulated to greatly improve pharmacokinetics & increase potency, with no evidence of protective function in multiple cancer cell lines

PETER HEIFETZ, Chief Executive Officer, Orpro Therapeutics

Q&A session & transition time between conference rooms

Afternoon Track Chair TBA

PANEL DISCUSSION:  
Sustainability Impact Of Different Drug Delivery Methods

•Inhalation

•Oral delivery

•Injection

Moderator: SENIOR REPRESENTATIVE, Quantum Si

Panellists:  
ENRICO ZAMBELLI, Sustainable Formulation Project Unit Manager, Chiesi

JACK ROGERS, Director of Neurochemistry, Harvard University

CATHERINE CAHILL, Assistant Professor, Harvard Medical School

VIVEK GUPTA, Associate Professor, St. John’s University

14:00

14:25

Q&A session & transition time between conference rooms

Q&A session & transition time between conference rooms

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

Linked

@OGConferences



15:15

Day Two   October 3 2025			
DRUG DISCOVERY PROGRAM		FORMULATION & DELIVERY PROGRAM	
SCREENING & HIT IDENTIFICATION CORAL 1	DEGRADERS & MOLECULAR GLUES CORAL 2	LARGE MOLECULE FORMULATION SEAGLASS	LARGE MOLECULE & RNA DELIVERY CORAL 3
<p><b>Small Molecule Discovery: Unfolding Precision Medicines Using Phenotypic Screening In Primary Human Cells</b></p> <ul style="list-style-type: none"><li>• Rationale for the use of phenotypic screening</li><li>• Considerations for establishing a high quality phenotypic screen</li><li>• Hit identification and de-convolution in human disease models</li></ul> <p>BETH HOFFMAN, President &amp; Chief Executive Officer, <b>Origami Therapeutics, Inc.</b></p>	<p><b>Novel Ultra High Density Screening For Molecular Glues</b></p> <p>PEGGY THOMPSON, Vice President, Head of Biology, <b>Plexium</b></p>	<p><b>INTERACTIVE</b></p> <p><i>PANEL DISCUSSION:</i> <b>Optimizing Formulation Of High Dosage Biologics</b></p> <ul style="list-style-type: none"><li>• Viscosity, aggregation, and stability issues</li><li>• Strategies for formulation optimization</li><li>• Scale-up and regulatory alignment</li></ul> <p><b>Moderator:</b> RAMESH KASHI, Former Senior Scientific Director, <b>Bristol Myers Squibb</b></p> <p><b>Panellists:</b> SUNITA YADAV, Associate Director, <b>Novartis</b> JAMIE TSUNG, Director, <b>Alnylam Pharmaceuticals</b> CRAIG BEHNKE, Executive Vice President, Production &amp; Development, <b>Lumen Bioscience</b></p>	<p><b>Toward Delivery Of Improved Efficacy, Greater Safety, &amp; Enhanced Patient Experience During &amp; After Treatment</b></p> <ul style="list-style-type: none"><li>• Erkki Ruoslahti’s “cellular zipcodes” and a novel delivery mechanism of action</li><li>• Improved efficacy: how?</li><li>• Greater safety: how?</li><li>• Enhanced patient experience: how?</li><li>• Challenges to preclinical development of product</li><li>• Future vision</li></ul> <p>DAVID LOYND, Chief Executive Officer, <b>EnduRx</b></p>
Q&A session & transition time between conference rooms			
<p><b>VS@Lilly: Enablement Of A Dedicated Platform For Identifying Novel Small-Molecule Binders</b></p> <p>The VS@Lilly project represents a significant advancement in computational chemistry, focusing on the development of a dedicated platform for identifying novel small-molecule binders. This platform supports routine ultra-large-scale virtual screening, leveraging advanced technology to explore commercially available chemical spaces and identify primary or backup chemical starting points. It features an extensive database with over 40 million off-the-shelf compounds and several billion compounds available through on-demand synthesis, all in various formats for efficient screening.</p> <p>SHANTHI NAGARAJAN, Director, <b>Eli Lilly</b></p>	<p><b>Predictive Modeling Of Degradер’s Oral Bioavailability &amp; In Vivo PK Properties</b></p> <ul style="list-style-type: none"><li>• Oral bioavailability of TPDs, especially larger sized bifunctional molecules (i.e. PROTAC), is one of the most challenging properties to be optimized for oral drug discovery</li><li>• A comprehensive in vivo data set were collected from public domain and 2D/3D descriptors were developed to establish predictive models for oral bioavailability</li><li>• We address the different behavior of predictive models by using data sets from different type of animal models</li><li>• Going beyond ML models, mechanistic based method was established to predict in vivo PK parameters</li></ul> <p>LEI JIA, Associate Director, Drug Discovery Data Science, <b>Johnson &amp; Johnson</b></p>	<p><b>Formulating Proteins For Maximum Stability</b></p> <ul style="list-style-type: none"><li>• Solid-state characterization of mRNA LNPs to identify formulation and lyophilization conditions to ensure long-term stability</li><li>• Predicting protein stability, including mAbs, in the solid state – formulation approaches to ensure long-term stability</li><li>• New technologies for in situ and non-destructive characterization of aseptic solid formulations</li></ul> <p>ERIC MUNSON, Professor, <b>Purdue University</b></p>	<p><b>Formulations For Pre-Filled Syring Delivery</b></p> <p>JAMIE TSUNG, Director, <b>Alnylam Pharmaceuticals</b></p>

Q&A session & transition time between conference rooms

BROCHURE  
CONTENTS

Welcome

Benefits of  
Attending

Sponsors

Special  
Event  
Features

Agenda at  
a Glance

Featured  
Speakers:  
Discovery

Featured  
Speakers:  
Formulation

All Speakers

Full  
Programme:  
Day One

Full  
Programme:  
Day Two

Venue  
Information

Book Now

Day Two | October 3 2025

DRUG DISCOVERY PROGRAM

SCREENING & HIT IDENTIFICATION

CORAL 1

Donor to Donor Variability in Pharmacology: Mole Hill or Mountain?

•Major transition towards using primary cell assays in support of drug discovery programs for autoimmune diseases to improve translation

•An analysis of >25 primary cell assays used for HTS and SAR will be presented, including an answer to the question of donor to donor variability

•Specific lessons and strategies learned to facilitate the use of these physiologically relevant assays will be shared

FABIEN VINCENT, Consultant, Former Pharmacology Lab Head, Pfizer

DEGRADERS & MOLECULAR GLUES

CORAL 2

Preclinical Evaluation Of Bms-986365: A First-In-Class Dual Ar Ligand-Directed Degradar And Antagonist For Mcrpc Therapy

•BMS-986365 is a heterobifunctional AR degrader and antagonist for wildtype and mutant AR

•Inhibits AR target gene transcription and cell proliferation more effectively than enzalutamide

•Maintains low AR protein despite elevated transcript levels

•Shows robust efficacy in cell line and patient-derived xenograft models

•Clinically lowers PSA in mCRPC post-ARPI, effective in resistant disease

SURENDRA NAYAK, Scientific Associate Director, Bristol Myers Squibb

FORMULATION & DELIVERY PROGRAM

LARGE MOLECULE FORMULATION

SEAGLASS

Attendees are welcome to join co-located sessions

LARGE MOLECULE & RNA DELIVERY

CORAL 3

Delivery Of Oligonucleotides To The Brain Via The Trans-Nasal Route In Neurodegenerative Rat Models

ANISHA DSOUZA, Research Fellow, Massachusetts Eye and Ear Infirmary, Harvard Medical School

END OF CONFERENCE

15:40

16:05

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Special Event Features

Agenda at a Glance

Featured Speakers: Discovery

Featured Speakers: Formulation

All Speakers

Full Programme: Day One

Full Programme: Day Two

Venue Information

Book Now

Linked In

@OGConferences





## VENUE INFORMATION

# Soak in Stunning Waterfront Views at Sheraton San Diego Resort

**Sheraton San Diego Resort dazzles guests with spectacular views of the marina or downtown skyline. Experience San Diego with a central location in the heart of the harbor, yet just minutes from San Diego Airport with a free shuttle.**

Enjoy being near downtown, Gaslamp Quarter, San Diego Zoo, and Petco Park, for a fun time in the city. Our newly renovated marina tower shines with coastal hues and modern amenities and our light-filled accommodations have a private balcony with seating. Enjoy picturesque views of the bay or marina in the classic bay tower guest rooms that also boast private balconies with seating. Stop by BreweryX for a refreshing brew or discover authentic Baja dishes at Rumorosa. Enjoy our sprawling outdoor pool complex, with ample opportunities to soak in the San Diego sun or lounge in poolside cabanas, cocktail in hand. Featuring over 130,000 sq ft of venue space accentuated by waterfront views, our San Diego Harbor Hotel is an inspired choice for weddings and meetings.



### Sheraton San Diego Resort

1380 Harbor Island Drive,  
San Diego, CA

[Explore the Hotel](#)

#### DIRECTIONS BY AIR

From San Diego International Airport (SAN), the hotel is just 1.5 miles from the airport.

**Shuttle:** Use the free Sheraton shuttle, available at Terminal 1 & Terminal 2. Look for the "Hotel Courtesy Shuttle" sign. If Shuttle is unavailable: Take the 992 bus from the airport to the Harbor Island Drive & Sheraton Way stop (5-minute ride). Walk 5 minutes to the hotel.

#### DIRECTIONS BY TRAM/BUS

The total journey from downtown via tram and bus should take around 20-30 minutes.

- Take the San Diego Trolley:
  - » Use the Green Line or another line that connects to the Santa Fe Depot station.
- Transfer to Bus or Walk:
  - » From Santa Fe Depot, take Bus 992 (Airport Route) toward the San Diego International Airport. Exit at the hotel stop near Harbor Island.
- Alternatively, walk approximately 30 minutes (1.5 miles) along Harbor Drive to the hotel.

## BROCHURE CONTENTS

[Welcome](#)

[Benefits of Attending](#)

[Sponsors](#)

[Special Event Features](#)

[Agenda at a Glance](#)

[Featured Speakers: Discovery](#)

[Featured Speakers: Formulation](#)

[All Speakers](#)

[Full Programme: Day One](#)

[Full Programme: Day Two](#)

[Venue Information](#)

[Book Now](#)

[Linked in](#)  
[@OGConferences](#)